(Q33579568)

English

Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence (English)

1 reference

Europe PubMed Central

28 July 2017

1 reference

based on heuristic

inferred from title

author name string

Xi Zheng

1

1 reference

Europe PubMed Central

28 July 2017

Xiao-Xing Cui

2

1 reference

Europe PubMed Central

28 July 2017

Zhi Gao

3

1 reference

Europe PubMed Central

28 July 2017

Yang Zhao

4

1 reference

Europe PubMed Central

28 July 2017

Yong Lin

5

1 reference

Europe PubMed Central

28 July 2017

Weichung Joe Shih

6

1 reference

Europe PubMed Central

28 July 2017

Mou-Tuan Huang

7

1 reference

Europe PubMed Central

28 July 2017

Yue Liu

8

1 reference

Europe PubMed Central

28 July 2017

Arnold Rabson

9

1 reference

Europe PubMed Central

28 July 2017

Bandaru Reddy

10

1 reference

Europe PubMed Central

28 July 2017

Chung S Yang

11

1 reference

Europe PubMed Central

28 July 2017

Allan H Conney

12

1 reference

Europe PubMed Central

28 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2010

1 reference

Europe PubMed Central

28 July 2017

Cancer Prevention Research

1 reference

Europe PubMed Central

28 July 2017

3

1 reference

Europe PubMed Central

28 July 2017

1

1 reference

Europe PubMed Central

28 July 2017

114-124

1 reference

Europe PubMed Central

28 July 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Statin drugs and risk of advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Statins and prostate cancer risk: a case-control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Mechanisms of the development of androgen independence in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Clinical Pharmacokinetics of Atorvastatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Hormone resistance in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Activation of mitogen-activated protein kinase associated with prostate cancer progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Prostate cancer in a transgenic mouse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Regulation of the mevalonate pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

21 June 2018

Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

31 October 2018

Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

31 October 2018

Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

31 October 2018

A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

31 October 2018

Myc-driven murine prostate cancer shares molecular features with human prostate tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

31 October 2018

Expression of cyclooxygenase-2 in prostate carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

31 October 2018

Androgen receptor mutations in prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

31 October 2018

Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803700

31 October 2018

Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20051379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/20051379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20051379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20051379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20051379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20051379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1940-6207.CAPR-09-0059

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33579568&oldid=1975792291"